Medincell’s Partner Teva presented New Data Providing Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) from Invega Sustenna® (paliperidone palmitate)
June 3, 2024
June 3, 2024
MedinCell’s partner Teva provides guidance for UZEDY in 2024 and an update on olanzapine LAI (mdc-TJK)
January 31, 2024
January 31, 2024
MedinCell’s partner Teva announces successful launch of UZEDY™
August 2, 2023
August 2, 2023
First FDA approval and US commercial launch, MedinCell enters new era
Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults
April 28, 2023
April 28, 2023
MedinCell’s partner Teva today announced refiling for approval of mdc-IRM and confirmed planned launch in the U.S. in H1 2023
November 3, 2022
November 3, 2022
MedinCell’s partner Teva confirms expectation for approval and commercialization in the US in H1 2023 for mdc-IRM/TEV46000
July 27, 2022
July 27, 2022
MedinCell’s partner Teva provides additional information regarding the New Drug Application for mdc-IRM
May 3, 2022
May 3, 2022
MedinCell provides additional information regarding the new drug application for mdc-IRM
